Hisamitsu Pharmaceutical Co., Inc. (HTSUF)

Hisamitsu Pharmaceutical Co., Inc. (HTSUF) Healthcare & Pipeline Overview

Hisamitsu Pharmaceutical Co., Inc., founded in 1847, specializes in manufacturing and distributing external pain relief products and transdermal drug delivery systems. With a market capitalization of $2.04B, the company's key brands include SALONPAS and MOHRUS, serving markets in Japan, the United States, and Asia.

What Is the Investment Thesis for HTSUF?

Hisamitsu Pharmaceutical Co., Inc. presents a stable investment opportunity within the healthcare sector, supported by its established brands and consistent profitability. The company's P/E ratio of 22.3 reflects a reasonable valuation, while its profit margin of 12.5% and gross margin of 59.0% indicate efficient operations. A dividend yield of 1.99% offers income potential for investors. Growth catalysts include the expansion of its transdermal drug delivery systems and the potential approval of HFT-290 for cancer pain. However, investors may want to evaluate risks associated with regulatory approvals and competition within the generic drug market. The company's beta of 0.52 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

HTSUF Key Highlights

• Market capitalization of $2.04B, reflecting its established position in the pharmaceutical market.
• P/E ratio of 22.3, indicating a reasonable valuation relative to earnings.
• Profit margin of 12.5%, demonstrating efficient operations and profitability.
• Gross margin of 59.0%, showcasing strong pricing power and cost management.
• Dividend yield of 1.99%, providing income potential for investors.

Who Are HTSUF's Competitors?

HTSUF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HTSUF's Key Strengths?

• Established brand recognition with SALONPAS.
• Expertise in transdermal drug delivery systems.
• Strong distribution network in key markets.
• Consistent profitability and financial stability.

What Are HTSUF's Weaknesses?

• Reliance on a limited number of key products.
• Exposure to generic competition.
• Dependence on regulatory approvals for new products.
• Limited presence in emerging markets compared to larger competitors.

What Could Drive HTSUF Stock Higher?

• Potential regulatory approval of HFT-290, a transdermal patch for cancer pain, which could expand the company's product portfolio and revenue streams.
• Expansion of transdermal drug delivery systems into new therapeutic areas, driven by the growing demand for non-invasive drug administration.
• Geographic expansion in Asia, capitalizing on the increasing healthcare expenditure and aging populations in the region.

What Are the Key Risks for HTSUF?

• Regulatory delays or rejection of HFT-290, impacting the company's growth prospects.
• Increasing competition from generic drug manufacturers, potentially eroding market share and pricing power.
• Product liability claims, which could result in significant financial losses and reputational damage.
• Economic downturns affecting consumer spending on healthcare products, reducing demand for Hisamitsu's products.

What Are the Growth Opportunities for HTSUF?

• Expansion of Transdermal Drug Delivery Systems: Hisamitsu has a significant opportunity to expand its transdermal drug delivery systems. The global transdermal drug delivery market is projected to reach $80 billion by 2028, driven by the advantages of non-invasive drug administration and improved patient compliance. Hisamitsu's existing portfolio of transdermal patches for pain relief, hormone therapy, and other conditions positions it well to capture a larger share of this growing market. The company can leverage its expertise to develop new transdermal products for various therapeutic areas, addressing unmet medical needs and driving revenue growth.
• Geographic Expansion in Asia: Hisamitsu can further expand its presence in the Asian market. The Asia-Pacific pharmaceutical market is one of the fastest-growing globally, driven by increasing healthcare expenditure and aging populations. Hisamitsu already has a presence in several Asian countries, but there is potential to expand into new markets and increase market share in existing ones. This expansion could involve establishing new distribution partnerships, launching new products tailored to local needs, and increasing marketing efforts to raise brand awareness.
• New Product Development and Innovation: Hisamitsu's continued investment in research and development can lead to the discovery and commercialization of new pharmaceutical products. The company's focus on transdermal drug delivery systems provides a platform for innovation in various therapeutic areas. By developing new products that address unmet medical needs, Hisamitsu can expand its product portfolio, attract new customers, and drive revenue growth. The development of HFT-290, a transdermal patch for cancer pain, exemplifies this growth opportunity.
• Strategic Partnerships and Acquisitions: Hisamitsu can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. Collaborating with other pharmaceutical companies, research institutions, or technology providers can provide access to new technologies, products, or markets. Acquisitions can also be used to expand the company's product portfolio or geographic presence. By carefully selecting partners and acquisition targets, Hisamitsu can accelerate its growth and strengthen its competitive position.
• Increased Focus on Over-the-Counter (OTC) Products: Hisamitsu can capitalize on the growing demand for over-the-counter (OTC) medications. The global OTC market is projected to reach $200 billion by 2025, driven by increasing self-care trends and the availability of more medications without a prescription. Hisamitsu's existing portfolio of OTC products, such as SALONPAS and BUTENALOCK, can be expanded to include new formulations and indications. The company can also increase its marketing efforts to raise awareness of its OTC products and drive sales.

What Opportunities Does HTSUF Have?

• Expansion into new therapeutic areas.
• Geographic expansion in Asia and other regions.
• Development of new transdermal drug delivery systems.
• Strategic partnerships and acquisitions.

What Threats Does HTSUF Face?

• Increasing competition from generic drug manufacturers.
• Stringent regulatory requirements and potential delays in approvals.
• Product liability claims.
• Economic downturns affecting consumer spending on healthcare products.

What Are HTSUF's Competitive Advantages?

• Established brand recognition with the SALONPAS brand, creating customer loyalty.
• Expertise in transdermal drug delivery systems, providing a competitive advantage in product development.
• Strong distribution network in Japan, the United States, and Asia.
• Consistent investment in research and development, leading to innovative products.

What Does HTSUF Do?

Founded in 1847 and headquartered in Tosu, Japan, Hisamitsu Pharmaceutical Co., Inc. has evolved into a prominent manufacturer and distributor of pharmaceuticals, quasi-drugs, and medical devices. The company is particularly known for its external pain relief products, marketed under well-recognized brands such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. These products cater to a broad consumer base seeking relief from muscle pain, joint stiffness, and other discomforts. Beyond pain relief, Hisamitsu also offers BUTENALOCK, a remedy for athlete's foot, and ALLEGRA FX, a sinus medication for allergies. Hisamitsu's product portfolio extends to transdermal drug delivery systems, including MOHRUS TAPE and MOHRUS PAP XR, which deliver analgesic and anti-inflammatory medication through the skin. These innovative delivery systems are also utilized for hormone replacement therapy, asthma treatment, and overactive bladder management, marketed under brands like FENTOS Tapes, NEOXY Tapes, and MENOAID Combipatch. The company continues to expand its offerings, with HFT-290, a transdermal patch for cancer pain, in development. Hisamitsu distributes its products across Japan, the United States, and Asia, solidifying its position as a global player in the pharmaceutical industry.

What Products and Services Does HTSUF Offer?

• Manufactures and sells pharmaceutical products.
• Produces and distributes quasi-drugs.
• Develops and markets medical devices.
• Specializes in external pain relieving drugs under the SALONPAS brand.
• Offers transdermal drug delivery systems, including patches for pain relief and hormone therapy.
• Provides remedies for athlete's foot and allergy medications.
• Sells products in Japan, the United States, and Asia.

How Does HTSUF Make Money?

• Develops and manufactures pharmaceutical products and medical devices.
• Markets and distributes products through various channels, including pharmacies and retailers.
• Generates revenue through the sale of prescription and over-the-counter medications.
• Invests in research and development to create new products and improve existing ones.

What Industry Does HTSUF Operate In?

Hisamitsu Pharmaceutical Co., Inc. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The global market for generic drugs is projected to reach $480 billion by 2026, driven by increasing healthcare costs and the expiration of patents on branded drugs. Hisamitsu differentiates itself through its focus on transdermal drug delivery systems and established brands like SALONPAS. Competitors include companies such as ARSUF (AstraZeneca PLC) and BRCTF (Bristol-Myers Squibb), which also operate in the broader pharmaceutical market.

Who Are HTSUF's Key Customers?

• Individuals seeking pain relief from muscle aches, joint stiffness, and other discomforts.
• Patients requiring hormone replacement therapy or treatment for overactive bladder.
• Consumers seeking remedies for athlete's foot and allergy symptoms.
• Healthcare providers who prescribe or recommend Hisamitsu's products.

FY2026 estForward Outlook

Wall Street analysts project Hisamitsu Pharmaceutical Co., Inc. revenue of about $162.47B for fiscal 2026, with EPS near $300.36.

F-Score 5/9Financial Health

Hisamitsu Pharmaceutical Co., Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.73 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 7%Key Financial Metrics

Return on equity for Hisamitsu Pharmaceutical Co., Inc. stands at 7.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.2%, showing how much profit it generates from its asset base. HTSUF trades at a trailing price-to-earnings ratio of 22.30, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.5%, the inverse of the P/E and a quick read on earnings relative to price.

Hisamitsu Pharmaceutical Co., Inc. (HTSUF) Valuation Context

Valued at $2.04B, HTSUF is classified as a mid-cap stock. Relative to its peer group, HTSUF's quantitative score of 48/100 is roughly in line with the peer average of 53/100.

Company Profile

Hisamitsu Pharmaceutical Co., Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tosu, JP. The company is led by CEO Kazuhide Nakatomi. HTSUF has traded publicly since 2010.

HTSUF Financials

HTSUF Latest News

No recent news available for HTSUF.

HTSUF Analyst Consensus

HTSUF MoonshotScore

HTSUF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources